LEXICON PHARMACEUTICALS, INC. (LXRX) Spending and interest coverage
- R&D / revenue · 12 months: Value 145.34%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 30.61%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 145.34% | Research and development expense / revenue. Period ending 2026-06-30. $60.27M ÷ $41.47M × 100 ≈ 145.34% |
| Stock-based compensation / revenue · 12 months | 30.61% | Share-based compensation / revenue. Period ending 2026-06-30. $12.69M ÷ $41.47M × 100 ≈ 30.61% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 60.27M USD | Research and Development Expense |
| Revenue | 41.47M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 12.69M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -54.50M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $60.27M | $41.47M | $12.69M | $-54.50M | (m) | 145.34% | 30.61% | (m) | (m) |
| 2026-03-31 | $58.57M | $69.64M | $12.55M | $-24.23M | (m) | 84.11% | 18.02% | (m) | (m) |
| 2025-12-31 | $61.12M | $49.80M | $12.52M | $-48.91M | (m) | 122.73% | 25.13% | (m) | (m) |
| 2025-09-30 | $76.49M | $45.86M | $11.22M | $-66.87M | (m) | 166.79% | 24.46% | (m) | (m) |
| 2025-06-30 | $83.52M | $33.42M | $10.58M | $-118.37M | (m) | 249.90% | 31.65% | (m) | (m) |
| 2025-03-31 | $85.41M | $6.17M | $12.24M | $-177.46M | (m) | 1384.29% | 198.38% | (m) | (m) |
| 2024-12-31 | $84.48M | $6.00M | $13.50M | $-197.12M | (m) | 1407.77% | 224.95% | (m) | (m) |
| 2024-09-30 | $72.56M | $5.12M | $15.17M | $-211.12M | (m) | 1416.30% | 296.19% | (m) | (m) |
| 2024-06-30 | $64.33M | $3.53M | $16.27M | $-197.06M | (m) | 1823.04% | 461.07% | (m) | (m) |
| 2024-03-31 | $61.23M | $2.20M | $15.23M | $-185.94M | (m) | 2779.53% | 691.19% | (m) | (m) |
| 2023-12-31 | $58.89M | $1.11M | $14.34M | $-171.75M | (m) | 5305.14% | 1291.89% | (m) | (m) |
| 2023-09-30 | $58.10M | $438.00K | $14.40M | $-155.29M | $8.78M | 13265.30% | 3286.76% | -17.68× | Reported |
| 2023-06-30 | $51.10M | $291.00K | $13.15M | $-128.75M | $5.75M | 17560.48% | 4517.53% | -22.40× | Reported |
| 2023-03-31 | $49.92M | (m) | $12.16M | $-108.52M | $4.49M | (m) | (m) | -24.16× | Reported |
| 2022-12-31 | $52.82M | $0.00 | $11.52M | $-100.76M | $2.78M | (m) | (m) | -36.24× | Reported |
| 2022-09-30 | $55.34M | (m) | $10.48M | $-95.81M | $1.97M | (m) | (m) | -48.59× | Reported |
| 2022-06-30 | $60.46M | (m) | $10.54M | $-95.68M | $1.28M | (m) | (m) | -74.81× | Reported |
| 2022-03-31 | $57.36M | (m) | $10.50M | $-89.63M | $745.00K | (m) | (m) | -120.31× | Reported |
| 2021-12-31 | $55.05M | $0.00 | $10.58M | $-87.09M | $802.00K | (m) | (m) | -108.59× | Reported |
| 2021-09-30 | $39.54M | $23.37M | $11.03M | $-69.22M | $677.00K | 169.18% | 47.19% | -102.24× | Reported |
| 2021-06-30 | $64.00M | $23.37M | $10.22M | $40.42M | $4.62M | 273.87% | 43.73% | 8.74× | Reported |
| 2021-03-31 | $111.05M | $23.40M | $11.69M | $-6.20M | $9.58M | 474.65% | 49.98% | -0.65× | Reported |
| 2020-12-31 | $153.62M | $23.40M | $13.27M | $-47.80M | $14.54M | 656.39% | 56.72% | -3.29× | Reported |
| 2020-09-30 | $193.24M | $-256.85M | $14.07M | $-87.56M | $19.57M | -75.23% | -5.48% | -4.48× | Reported |
| 2020-06-30 | $179.75M | $29.07M | $15.73M | $50.44M | $20.65M | 618.43% | 54.12% | 2.44× | Reported |
| 2020-03-31 | $135.08M | $29.90M | $15.24M | $96.48M | $20.69M | 451.78% | 50.97% | 4.66× | Reported |
| 2019-12-31 | $91.92M | $32.33M | $14.22M | $141.44M | $20.68M | 284.32% | 43.98% | 6.84× | Reported |
| 2019-09-30 | $63.63M | $289.00M | $13.59M | $176.29M | $20.71M | 22.02% | 4.70% | 8.51× | Reported |
| 2019-06-30 | $50.73M | $3.65M | $12.90M | $-71.31M | $20.76M | 1391.36% | 353.84% | -3.44× | Reported |
| 2019-03-31 | $64.57M | $9.19M | $12.03M | $-83.04M | $20.78M | 702.60% | 130.94% | -4.00× | Reported |
| 2018-12-31 | $100.24M | $26.58M | $11.70M | $-103.28M | $20.78M | 377.09% | 44.00% | -4.97× | Reported |
| 2018-09-30 | $135.30M | $78.86M | $11.11M | $-122.22M | $17.72M | 171.56% | 14.08% | -6.90× | Reported |
| 2018-06-30 | $160.67M | $98.95M | $10.81M | $-128.70M | $14.08M | 162.38% | 10.92% | -9.14× | Reported |
| 2018-03-31 | $161.01M | $97.25M | $10.31M | $-132.16M | $10.51M | 165.57% | 10.61% | -12.57× | Reported |
| 2017-12-31 | $156.81M | $90.33M | $9.47M | $-136.68M | $6.98M | 173.59% | 10.49% | -19.57× | Reported |
| 2017-09-30 | $150.05M | $80.33M | $8.94M | $-137.23M | $6.46M | 186.81% | 11.13% | -21.26× | Reported |
| 2017-06-30 | $163.45M | $81.10M | $8.29M | $-142.64M | $6.48M | 201.54% | 10.23% | -22.01× | Reported |
| 2017-03-31 | $184.73M | $89.14M | $7.85M | $-145.77M | $6.51M | 207.25% | 8.80% | -22.41× | Reported |
| 2016-12-31 | $178.15M | $83.34M | $7.45M | $-137.16M | $6.57M | 213.77% | 8.94% | -20.89× | Reported |
| 2016-09-30 | $168.19M | $187.58M | $7.15M | $-17.46M | $6.61M | 89.66% | 3.81% | -2.64× | Reported |
| 2016-06-30 | $138.77M | $160.43M | $6.89M | $-16.21M | $6.65M | 86.50% | 4.30% | -2.44× | Reported |
| 2016-03-31 | $111.32M | $140.72M | $6.72M | $-5.88M | $6.67M | 79.11% | 4.78% | -0.88× | Reported |
| 2015-12-31 | $95.19M | $130.01M | $6.84M | $1.47M | $6.72M | 73.21% | 5.26% | 0.22× | Reported |
| 2015-09-30 | $84.78M | $24.22M | $6.91M | $-90.34M | $5.94M | 350.08% | 28.53% | -15.22× | Reported |
| 2015-06-30 | $85.77M | $24.07M | $6.73M | $-97.00M | $4.70M | 356.36% | 27.97% | -20.65× | Reported |
| 2015-03-31 | $86.19M | $24.37M | $6.78M | $-96.42M | $3.50M | 353.69% | 27.84% | -27.56× | Reported |
| 2014-12-31 | $89.28M | $22.85M | $7.08M | $-100.37M | $2.25M | 390.65% | 30.98% | -44.55× | Reported |
| 2014-09-30 | $89.51M | $2.78M | $7.28M | $-113.89M | $1.84M | 3217.51% | 261.57% | -61.97× | Reported |
| 2014-06-30 | $90.80M | $2.60M | $7.53M | $-104.78M | $1.88M | 3491.08% | 289.62% | -55.70× | Reported |
| 2014-03-31 | $93.31M | $2.14M | $7.56M | $-107.29M | $1.92M | 4362.23% | 353.53% | -55.82× | Reported |
| 2013-12-31 | $89.68M | $2.22M | $7.42M | $-102.37M | $1.97M | 4036.09% | 333.98% | -51.94× | Reported |
| 2013-09-30 | $90.41M | $1.03M | $7.32M | $-109.89M | $2.01M | 8777.57% | 710.49% | -54.56× | Reported |
| 2013-06-30 | $84.20M | $1.16M | $7.16M | $-107.73M | $2.05M | 7233.76% | 615.12% | -52.58× | Reported |
| 2013-03-31 | $79.86M | $1.15M | $6.89M | $-104.59M | $2.08M | 6950.74% | 599.30% | -50.21× | Reported |
| 2012-12-31 | $82.57M | $1.09M | $6.50M | $-108.42M | $2.11M | 7582.55% | 596.42% | -51.28× | Reported |
| 2012-09-30 | $89.69M | $1.21M | $6.26M | $-117.27M | $2.15M | 7388.06% | 515.49% | -54.67× | Reported |
| 2012-06-30 | $90.15M | $1.20M | $6.10M | $-113.90M | $2.18M | 7531.66% | 509.44% | -52.29× | Reported |
| 2012-03-31 | $90.94M | $1.55M | $5.95M | $-114.34M | $2.46M | 5856.02% | 383.32% | -46.52× | Reported |
| 2011-12-31 | $91.83M | $1.85M | $5.71M | $-114.09M | $2.53M | 4966.36% | 308.65% | -45.13× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $78.52M | $4.91M | $5.48M | $-95.72M | $2.72M | 1599.84% | 111.61% | -35.20× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $81.24M | $10.70M | $5.27M | $-89.96M | $2.97M | 759.23% | 49.29% | -30.33× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |